Claritas Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLAZF research report →
About the company
Operating as a clinical-stage specialty pharmaceutical entity, Claritas Pharmaceuticals, Inc. is dedicated to the creation and market introduction of medical therapies addressing significant patient needs that are currently unfulfilled. Established in 2014, the company was previously known as Kalytera Therapeutics, Inc.
- CEO
- Robert Farrell
- IPO
- 2016
- Employees
- 3
- HQ
- San Rafael, CA, US
Price Chart
- Market Cap
- $3.66K
- P/E
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.05
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -436.27%
- ROIC
- 482.39%
- Revenue
- $0 · 0.00%
- Net Income
- $4.21M · 119.85%
- EPS
- $0.16 · 116.84%
- Op Income
- $-3,276,000
- FCF YoY
- 95.23%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.64
- Avg Volume
- 253.712
Get TickerSpark's AI analysis on CLAZF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our CLAZF coverage
Recent articles, reports, and earnings notes.
No research on CLAZF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLAZF report →Similar companies
Peers in the same neighborhood.